Hopp til hovedinnhold

Hjernesvulst hos voksne

Sist oppdatert: Sist revidert:
Sist revidert av:

Definisjon:
Primære intrakraniale svulster omfatter alle svulster ovenfor foramen magnum som utgår fra hjernevev, hjernehinner, hjernenerver og hypofyse. 
Forekomst:
Aldersjustert insidens (uten metastasene) er rundt 20 per 100 000 per år
Symptomer:
Avhenger av lokalisasjon, type og veksthastighet. Hodepine, krampeanfall, endret mental status og kvalme er vanlige debutsymptom
Funn:
Er relatert til lokalisasjon og veksthastighet. Epileptiske anfall og fokalnevrologiske utfall kan være tidlige tegn
Diagnostikk:
Cerebral MR og histologisk undersøkelse av svulsten er de to viktigste diagnostiske hjelpemidlene
Behandling:
Kirurgi, strålebehandling, i noen tilfeller kjemoterapi. 
  1. Louis DN, Perry A, Reifenberger G et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131(6): 803-20. pmid:27157931 PubMed  
  2. Helseth E, Meling T, Lundar T, et al. Intrakraniale svulster hos voksne. Tidsskr Nor Lægeforen 2003; 123: 456-61. PubMed  
  3. Eirik Helseth, Bernt J. Due-Tønnessen, Tryggve Lundar et al. Intrakraniale svulster hos barn. Tidsskr Nor Legeforen 2003; 123: 451-5. pmid:12643055 PubMed  
  4. Whittle IR, Smith C, Navoo P, Collie D. Meningiomas. Lancet 2004; 363: 1535-43. PubMed  
  5. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol 2010; 99: 307-14. pmid:20821343 PubMed  
  6. Saeger W, Lüdecke DK, Buchfelder M, et al. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 2007; 156: 203-16. pmid:17287410 PubMed  
  7. Kreftregisteret. Cancer in Norway 2017. Oslo: Kreftregisteret, 2018, www.kreftregisteret.no. www.kreftregisteret.no  
  8. Perkins A, Liu G. Primary brain tumors in adults: diagnosis and treatment. Am Fam Physician. 2016 Feb 1;93(3):211-217B.
  9. Marta GN, Murphy E, Chao S et al. The incidence of second brain tumors related to cranial irradiation. Expert Rev Anticancer Ther 2015; 15: 295-304. pmid:25482749 PubMed  
  10. Salvatore JR, Weitberg AB, Mehta S. Nonionizing electromagnetic fields and cancer: a review. Oncology (Huntingt) 1996; 10: 563 - 74. PubMed  
  11. Frei P, Poulsen AH, Johansen C, et al. Use of mobile phones and risk of brain tumours: uppdate of Danish cohort study. BMJ 2011; 343: d6387. BMJ (DOI)  
  12. Inskip PD, Mellemkjær L, Gridley G, Olsen JH. Incidence of intracranial tumors following hospitalization for head injuries (Denmark). Cancer Causes Control 1998; 9: 109 - 16. PubMed  
  13. Little MP, Rajaraman P, Curtis RE et al. Mobile phone use and glioma risk: comparison of epidemiological study results with incidence trends in the United States. BMJ 2012. pmid:22403263 PubMed  
  14. Wong ET, Wu JK. Clinical presentation and diagnosis of brain tumors. UpToDate. Last updated Feb 2017. UpToDate  
  15. Wen PY, Schiff D, Kesari S, Drappatz J, Gigas D, Doherty L. Medical management of patients with brain tumors. J Neurooncol 2006; 80: 313-32. PubMed  
  16. Helseth R, Helseth E, Johannesen TB, et al. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand 2010; 122: 159-67. pmid:20298491 PubMed  
  17. Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA 2012; 308: 1881-8. pmid:23099483 PubMed  
  18. Hasseleid BF, Meling TR, Rønning P, et al. Surgery for convexity meningioma: Simpson Grade I resection as the goal: clinical article. J Neurosurg 2012; 117: 999-1006. pmid:23061394 PubMed  
  19. Lassen B, Helseth E, Egge A, et al. Surgical mortality and selected complications in 273 consecutive craniotomies for intracranial tumors in pediatric patients. Neurosurgery 2012; 70: 936-43. pmid:21993188 PubMed  
  20. Lassen B, Helseth E, Rønning P, et al. Surgical mortality at 30 days and complications leading to recraniotomy in 2630 consecutive craniotomies for intracranial tumors. Neurosurgery 2011; 68: 1259-68. pmid:21273920 PubMed  
  21. Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008; 62: 564-76. pmid:18425006 PubMed  
  22. Myrseth E, Møller P, Pedersen PH, Lund-Johansen M. Vestibular schwannoma: surgery or gamma knife radiosurgery? A prospective, nonrandomized study. Neurosurgery 2009; 64: 654-61. pmid:19197222 PubMed  
  23. Storstein A, Helseth E, Johannesen TB et al. Høygradige gliomer hos voksne. Tidsskr Nor Legeforen 2011; 131: 238-41. doi:10.4045/tidsskr.09.1362 DOI  
  24. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013; 31: 344-50. pmid:23071237 PubMed  
  25. Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K. Chemotherapy wafers for high grade glioma. Cochrane Database of Systematic Reviews 2011, Issue 3. Art. No.: CD007294. DOI: 10.1002/14651858.CD007294.pub2. DOI  
  26. Hart MG, Garside R, Rogers G, Stein K, Grant R. Temozolomide for high grade glioma. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD007415. DOI: 10.1002/14651858.CD007415.pub2. DOI  
  27. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10(5): 459. pmid:19269895 PubMed  
  28. Cairncross G, Wang M, Shaw E, et al.: Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.. J Clin Oncol 2013; 31: 337-43. pmid:23071247 PubMed  
  29. Ferreri AJ. How I treat primary CNS lymphoma. Blood 2011; 118: 510-22. pmid:21613254 PubMed  
  30. Ameratunga M, Pavlakis N, Wheeler H. Anti‐angiogenic therapy for high‐grade glioma. Cochrane Database of Systematic Reviews 2018, Issue 11. Art. No.: CD008218. DOI: 10.1002/14651858.CD008218.pub4. DOI  
  31. Sarmiento JM, Venteicher AS, Patil CG. Early versus delayed postoperative radiotherapy for treatment of low‐grade gliomas. Cochrane Database of Systematic Reviews 2015, Issue 6. Art. No.: CD009229. DOI: 10.1002/14651858.CD009229.pub2. DOI  
  32. van den Bent MJ. Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. Neuro Oncol. 2014. 16(12): 1570–1574. pmid: 25355680 PubMed  
  33. Buckner JC, Shaw EG, Pugh SL et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med 2016; 374(14): 1344-55. pmid:27050206 PubMed  
  34. Baumert BG, Hegi ME, van den Bent MJ et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 2016; 17(11): 1521-32. pmid:27686946 PubMed  
  35. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507. PubMed  
  36. Lecavalier‐Barsoum M, Quon H, Abdulkarim B. Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database of Systematic Reviews 2014, Issue 5. Art. No.: CD007104. DOI: 10.1002/14651858.CD007104.pub2. The Cochrane Library  
  37. Omuro A, DeAngels LM. Glioblastoma and Other Malignant Gliomas A Clinical Review. JAMA 2013; 310: 1842-50. pmid:24193082 PubMed  
  38. Rogers L1, Barani I, Chamberlain M et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 2015; 122: 4-23. pmid:25343186 PubMed  
  39. Breivik CN, Varughese JK, Wentzel-Larsen T, et al. Conservative management of vestibular schwannoma--a prospective cohort study: treatment, symptoms, and quality of life. Neurosurgery 2012; 70: 1072-80. pmid:22067416 PubMed  
  40. Myrseth E, Pedersen PH, Møller P, Lund-Johansen M. Treatment of vestibular schwannomas. Why, when and how?. Acta Neurochir (Wien) 2007; 149: 647-60. pmid:17558460 PubMed  
  41. Varughese JK, Wentzel-Larsen T, Pedersen PH, et al. Gamma knife treatment of growing vestibular schwannoma in Norway: a prospective study. Int J Radiat Oncol Biol Phys 2012; 84: e161-6. PMID: 22682805 PubMed  
  42. Lin EP, Crane BT. The Management and Imaging of Vestibular Schwannomas. AJNR Am J Neuroradiol 2017; 38: 2034-43. pmid:28546250 PubMed  
  43. Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA 2017; 317: 516-24. pmid:28170483 PubMed  
  44. Varughese RK, Lind-Landström T, Habberstad AH et al. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III. J Clin Pathol 2016; 69: 26-34. pmid:26188054 PubMed  
  45. Brandes AA, Tosoni A, Cavallo G et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 2006; 24(29): 4746. pmid:16954518 PubMed  
  46. National Institute for Health and Care Excellence. Brain tumours (primary) and brain metastases in adults. NICE Guideline NG 99. Published July 2018. Siden besøkt 17.12.2018. www.nice.org.uk  
  • Tor Brommeland, dr. med., spesialist i nevrokirurgi ved Oslo Universitetssykehus Ullevål og Sørlandet Sykehus Kristiansand

Tidligere fagmedarbeidere

  • Eirik Helseth, professor i nevrokirurgi, Oslo universitetssykehus
  • Petter Brandal, overlege i nevrooonkologi, Oslo universitetssykehus
  • Magnus Olivecrona, överläkare, Neurokirurgiska kliniken, Norrlands universitetssjukhus, Umeå (Medibas)
  • Espen Dietrichs, professor og avdelingsoverlege, Universitetet i Oslo og Nevrologisk avdeling, Rikshospitalet, Oslo